These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22806594)

  • 1. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.
    Uhlin M; Gertow J; Uzunel M; Okas M; Berglund S; Watz E; Brune M; Ljungman P; Maeurer M; Mattsson J
    Clin Infect Dis; 2012 Oct; 55(8):1064-73. PubMed ID: 22806594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
    Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant.
    Comoli P; Basso S; Labirio M; Baldanti F; Maccario R; Locatelli F
    Blood Cells Mol Dis; 2008; 40(1):68-70. PubMed ID: 17904879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
    Peggs KS; Mackinnon S
    Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients.
    Li Pira G; Ivaldi F; Starc N; Landi F; Rutella S; Locatelli F; Sacchi N; Tripodi G; Manca F
    Transfusion; 2014 Dec; 54(12):3145-54. PubMed ID: 25041366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T; Matthes-Martin S; Richard C; Lion T; Fuhrer M; Hamprecht K; Handgretinger R; Peters C; Schuster FR; Beck R; Schumm M; Lotfi R; Jahn G; Lang P
    Br J Haematol; 2006 Jul; 134(1):64-76. PubMed ID: 16803570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive cellular immunotherapy for viral diseases.
    Fujita Y; Rooney CM; Heslop HE
    Bone Marrow Transplant; 2008 Jan; 41(2):193-8. PubMed ID: 17982497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
    Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
    Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
    Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
    Lucas KG; Salzman D; Garcia A; Sun Q
    Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
    Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease.
    McAulay KA; Haque T; Urquhart G; Bellamy C; Guiretti D; Crawford DH
    J Immunol; 2009 Mar; 182(6):3892-901. PubMed ID: 19265169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
    J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
    J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.
    Mackinnon S; Thomson K; Verfuerth S; Peggs K; Lowdell M
    Blood Cells Mol Dis; 2008; 40(1):63-7. PubMed ID: 17869548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients.
    Dong L; Gao ZY; Chang LJ; Liang Y; Tan XY; Liu JH; Yu XJ; Yang FH; Xie Y; Lu DP
    J Pediatr Hematol Oncol; 2010 Jan; 32(1):e31-7. PubMed ID: 20051775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient.
    Balduzzi A; Lucchini G; Hirsch HH; Basso S; Cioni M; Rovelli A; Zincone A; Grimaldi M; Corti P; Bonanomi S; Biondi A; Locatelli F; Biagi E; Comoli P
    Bone Marrow Transplant; 2011 Jul; 46(7):987-92. PubMed ID: 20921942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update.
    Feuchtinger T; Richard C; Pfeiffer M; Neuhäuser F; Lücke J; Handgretinger R; Greil J; Bader P; Klingebiel T; Schlegel PG; Jahn G; Niethammer D; Lang P
    Klin Padiatr; 2005; 217(6):339-44. PubMed ID: 16307420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation.
    Morita Y; Hosokawa M; Ebisawa M; Sugita T; Miura O; Takaue Y; Heike Y
    Bone Marrow Transplant; 2005 Nov; 36(9):803-11. PubMed ID: 16113668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.